Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
Author :
Publisher : Academic Press
Total Pages : 258
Release :
ISBN-10 : 9780128215852
ISBN-13 : 0128215852
Rating : 4/5 (852 Downloads)

Book Synopsis Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies by : Shi Hu

Download or read book Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies written by Shi Hu and published by Academic Press. This book was released on 2022-11-11 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibody therapies in cancer, including novel engineered antibody drugs and other sensitizers. The book gives insights into the landscape of anti-EGFR based cancer treatments, the challenges of targeted therapy, and a glimpse into the future of antibody therapy. It offers pertinent science information on strategies used for the rational design and discovery of novel sensitizing agents, and in addition, translational studies involving pre-clinical and clinical design. This book is an indispensable resource for cancer researchers, medicinal chemists and other biomedical scientists.Finally, the book covers basic science strategies used in drug discovery and preclinical evaluation focused on EGFR blockage resistance, as well as clinical trial methodology, including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new anticancer sensitizers for anti-EGFR drug resistance. - Presents detailed descriptions on the history, chemistry, mechanism of action, structure-function relationships, pharmacology, side effects, dosing and formulation of new sensitizers to anti-EGFR antibodies - Provides molecular structures for all novel anticancer drugs, along with strategies to overcome resistance to anti-EGFR antibodies - Encompasses up-to-date information on the cancer drug discovery process, including new research tools, tumor-targeting strategies, and fundamental concepts in emerging areas of precision medicine


Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies Related Books

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
Language: en
Pages: 258
Authors: Shi Hu
Categories: Science
Type: BOOK - Published: 2022-11-11 - Publisher: Academic Press

GET EBOOK

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies presents a description of the sensitizers used to overcome resistance to anti-EGFR targeted antibo
Multi-targeted Tyrosine Kinase Inhibitors in the Treatment of Cancer and Neurodegenerative Disorders
Language: en
Pages: 124
Authors: Halilibrahim Ciftci
Categories: Science
Type: BOOK - Published: 2024-08-07 - Publisher: Frontiers Media SA

GET EBOOK

Tyrosine kinases, which catalyze the transfer of a phosphate from ATP to a hydroxyl group of a tyrosine residue, play a plethora of roles in the regulation of d
Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal
Language: en
Pages: 444
Authors:
Categories: Computers
Type: BOOK - Published: 2023-08-30 - Publisher: Elsevier

GET EBOOK

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to an
Overcoming Cancers Resistant to HER-2 Antibodies
Language: en
Pages: 232
Authors: Benjamin Bonavida
Categories: Medical
Type: BOOK - Published: 2024-07-15 - Publisher: Academic Press

GET EBOOK

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibo
Clinical Radiation Oncology E-Book
Language: en
Pages: 2253
Authors: Leonard L. Gunderson
Categories: Medical
Type: BOOK - Published: 2015-06-16 - Publisher: Elsevier Health Sciences

GET EBOOK

Perfect for radiation oncology physicians and residents needing a multidisciplinary, treatment-focused resource, this updated edition continues to provide the l